Original-Research: DEAG Deutsche Entertainment AG - von Montega AG

Einstufung von Montega AG zu DEAG Deutsche Entertainment AG

Unternehmen: DEAG Deutsche Entertainment AG ISIN: DE000A0Z23G6

Anlass der Studie: Update
Empfehlung: Buy
seit: 01.12.2020
Kursziel: 4,10
Kursziel auf Sicht von: 12 months
Letzte Ratingänderung: -
Analyst: Henrik Markmann

DEAG closed Q3/20 with positive EBITDA despite significant negative effects due to corona crisis

Last Friday, DEAG published its Q3 report. As expected, the financial ratios were strongly impacted by the COVID-19 pandemic and therefore well below the prior-year figures. DEAG has confirmed its annual targets until the end of December despite the extension of the “lockdown light” in Germany.

[TABLE]

Q3/20 sales fell strongly by -87.4% yoy to a mere EUR 7.4m. Given that DEAG had to either cancel or postpone all major events in Q3/20 due to the corona-related restrictions in the live entertainment industry this did not come as a surprise. We had already anticipated a substantial decline as well (MONe: EUR 4.5m). CTS Eventim and Live Nation, the two much bigger competitors, also had to post a significant downturn in sales in Q3/20 of -92.0% and -95.1% yoy respectively. On the bottom line, DEAG suffered a significant decline in EBITDA of -87.2% yoy in Q3/20 (MONe: -83.5% to EUR 0.8m). However, the company remained in positive territory at EUR 0.6m thanks to a stringent management of selling, general and administration expenses as well as a comprehensive insurance coverage (EBITDA CTS: EUR -15.0m; Live Nation: EUR -384.5m). Liquid funds remained stable after nine months at EUR 41.6m (30.06.2020: EUR 39.9m), not least because of the heavily reduced SGA costs (-48.7% yoy to EUR 4.3m) as well as raising of external capital of some EUR 2m.

Although the “lockdown light” has been extended until the end of December, DEAG confirmed its annual target, thus expecting EBITDA to at least break even. As the company had already reported an EBITDA of EUR 0.3m after nine months and is expected to receive insurance benefits in the final quarter due to the cancelled „Christmas Gardens“ plus the financial assistance in November and December announced by the German government, we stick to our forecast of a full-year EBITDA of EUR 0.8m. Whilst there is still no visibility as to when the live entertainment industry will see a revival next year, DEAG already has a sales basis of over EUR 100m resulting from events already planned. In combination with vaccines that will become available soon as well as reliable rapid tests, DEAG should be well positioned with a view to 2021, which is why we keep our forecasts unchanged.

Conclusion: The weak operating development in Q3/20 is not surprising and already priced in by the heavy drop in share price. Having in mind the foreseeable recovery in 2021 and 2022 we stick to our turnaround scenario and confirm our buy recommendation with an unchanged price target of EUR 4.10.

+++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Bitte lesen Sie unseren RISIKOHINWEIS / HAFTUNGSAUSSCHLUSS unter http://www.montega.de +++

About Montega:

Montega AG is one of the leading independent German research institutions with a strong focus on German SMEs. The Coverage Universe includes stocks from the MDAX, TecDAX and SDAX as well as selected second-line stocks and is constantly being expanded through successful stock picking. Montega is an outsourced research provider for institutional investors and focuses on publishing research as well as on organizing roadshows, field trips and conferences. The company addresses long-term oriented value investors, asset managers and Family offices primarily from Germany, Switzerland and Luxembourg. The analysts of Montega are characterized by excellent and frequent contacts to the top management, in-depth market knowledge and many years of experience in the analysis of German small and mid-cap companies.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/21904.pdf

Kontakt für Rückfragen
Montega AG - Equity Research
Tel.: +49 (0)40 41111 37-80
Web: www.montega.de
E-Mail: research@montega.de

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.